MAINZ BIOMED NV (MYNZ) Fundamental Analysis & Valuation

NASDAQ:MYNZ • NL0015000LC2

Current stock price

0.8441 USD
+0.02 (+2.07%)
At close:
0.7672 USD
-0.08 (-9.11%)
After Hours:

This MYNZ fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. MYNZ Profitability Analysis

1.1 Basic Checks

  • MYNZ had negative earnings in the past year.
  • MYNZ had a negative operating cash flow in the past year.
  • MYNZ had negative earnings in each of the past 5 years.
  • MYNZ had a negative operating cash flow in each of the past 5 years.
MYNZ Yearly Net Income VS EBIT VS OCF VS FCFMYNZ Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

  • MYNZ has a Return On Assets of -220.85%. This is amonst the worse of the industry: MYNZ underperforms 90.15% of its industry peers.
  • The Return On Equity of MYNZ (-858.34%) is worse than 79.92% of its industry peers.
Industry RankSector Rank
ROA -220.85%
ROE -858.34%
ROIC N/A
ROA(3y)-154.86%
ROA(5y)-133.82%
ROE(3y)-451.51%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MYNZ Yearly ROA, ROE, ROICMYNZ Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800

1.3 Margins

  • MYNZ has a better Gross Margin (64.31%) than 78.96% of its industry peers.
  • In the last couple of years the Gross Margin of MYNZ has grown nicely.
  • The Profit Margin and Operating Margin are not available for MYNZ so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 64.31%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y27.49%
GM growth 5YN/A
MYNZ Yearly Profit, Operating, Gross MarginsMYNZ Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K -5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. MYNZ Health Analysis

2.1 Basic Checks

  • MYNZ does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • MYNZ has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, MYNZ has more shares outstanding
  • Compared to 1 year ago, MYNZ has an improved debt to assets ratio.
MYNZ Yearly Shares OutstandingMYNZ Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 500K 1M 1.5M 2M
MYNZ Yearly Total Debt VS Total AssetsMYNZ Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

  • MYNZ has an Altman-Z score of -16.41. This is a bad value and indicates that MYNZ is not financially healthy and even has some risk of bankruptcy.
  • MYNZ has a worse Altman-Z score (-16.41) than 81.47% of its industry peers.
  • MYNZ has a Debt/Equity ratio of 0.44. This is a healthy value indicating a solid balance between debt and equity.
  • Looking at the Debt to Equity ratio, with a value of 0.44, MYNZ is doing worse than 70.46% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.44
Debt/FCF N/A
Altman-Z -16.41
ROIC/WACCN/A
WACC6.07%
MYNZ Yearly LT Debt VS Equity VS FCFMYNZ Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 10M -10M -20M

2.3 Liquidity

  • A Current Ratio of 0.52 indicates that MYNZ may have some problems paying its short term obligations.
  • MYNZ's Current ratio of 0.52 is on the low side compared to the rest of the industry. MYNZ is outperformed by 90.54% of its industry peers.
  • MYNZ has a Quick Ratio of 0.52. This is a bad value and indicates that MYNZ is not financially healthy enough and could expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 0.43, MYNZ is doing worse than 90.54% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.52
Quick Ratio 0.43
MYNZ Yearly Current Assets VS Current LiabilitesMYNZ Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. MYNZ Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 65.47% over the past year.
  • Looking at the last year, MYNZ shows a decrease in Revenue. The Revenue has decreased by -0.17% in the last year.
  • The Revenue has been growing by 26.14% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)65.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%86.55%
Revenue 1Y (TTM)-0.17%
Revenue growth 3Y15.51%
Revenue growth 5Y26.14%
Sales Q2Q%-44.95%

3.2 Future

  • MYNZ is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.04% yearly.
  • The Revenue is expected to grow by 133.71% on average over the next years. This is a very strong growth
EPS Next Y83.39%
EPS Next 2Y38.62%
EPS Next 3Y24.17%
EPS Next 5Y15.04%
Revenue Next Year-17.68%
Revenue Next 2Y-7.02%
Revenue Next 3Y32.9%
Revenue Next 5Y133.71%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
MYNZ Yearly Revenue VS EstimatesMYNZ Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 100M 200M 300M
MYNZ Yearly EPS VS EstimatesMYNZ Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -20 -40 -60

More info and screens

Find the best growth stocksShow best growing peers

1

4. MYNZ Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for MYNZ. In the last year negative earnings were reported.
  • Also next year MYNZ is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MYNZ Price Earnings VS Forward Price EarningsMYNZ Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MYNZ Per share dataMYNZ EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15 -20

4.3 Compensation for Growth

  • A more expensive valuation may be justified as MYNZ's earnings are expected to grow with 24.17% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.62%
EPS Next 3Y24.17%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. MYNZ Dividend Analysis

5.1 Amount

  • No dividends for MYNZ!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MYNZ Fundamentals: All Metrics, Ratios and Statistics

MAINZ BIOMED NV

NASDAQ:MYNZ (3/11/2026, 8:14:19 PM)

After market: 0.7672 -0.08 (-9.11%)

0.8441

+0.02 (+2.07%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)09-26
Earnings (Next)03-30
Inst Owners12.84%
Inst Owner ChangeN/A
Ins Owners17.41%
Ins Owner Change46.01%
Market Cap7.65M
Revenue(TTM)894.00K
Net Income(TTM)-21.65M
Analysts82.86
Price Target14.28 (1591.74%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 8.55
P/FCF N/A
P/OCF N/A
P/B 3.03
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-22.36
EYN/A
EPS(NY)-1.38
Fwd EYN/A
FCF(TTM)-1.74
FCFYN/A
OCF(TTM)-1.71
OCFYN/A
SpS0.1
BVpS0.28
TBVpS-0.16
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -220.85%
ROE -858.34%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 64.31%
FCFM N/A
ROA(3y)-154.86%
ROA(5y)-133.82%
ROE(3y)-451.51%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y27.49%
GM growth 5YN/A
F-Score5
Asset Turnover0.09
Health
Industry RankSector Rank
Debt/Equity 0.44
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 27.98%
Cap/Sales 31.92%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.52
Quick Ratio 0.43
Altman-Z -16.41
F-Score5
WACC6.07%
ROIC/WACCN/A
Cap/Depr(3y)139.31%
Cap/Depr(5y)92.63%
Cap/Sales(3y)121.7%
Cap/Sales(5y)74.12%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)65.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%86.55%
EPS Next Y83.39%
EPS Next 2Y38.62%
EPS Next 3Y24.17%
EPS Next 5Y15.04%
Revenue 1Y (TTM)-0.17%
Revenue growth 3Y15.51%
Revenue growth 5Y26.14%
Sales Q2Q%-44.95%
Revenue Next Year-17.68%
Revenue Next 2Y-7.02%
Revenue Next 3Y32.9%
Revenue Next 5Y133.71%
EBIT growth 1Y30.87%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y25.08%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y19.02%
OCF growth 3YN/A
OCF growth 5YN/A

MAINZ BIOMED NV / MYNZ Fundamental Analysis FAQ

What is the fundamental rating for MYNZ stock?

ChartMill assigns a fundamental rating of 2 / 10 to MYNZ.


What is the valuation status of MAINZ BIOMED NV (MYNZ) stock?

ChartMill assigns a valuation rating of 1 / 10 to MAINZ BIOMED NV (MYNZ). This can be considered as Overvalued.


Can you provide the profitability details for MAINZ BIOMED NV?

MAINZ BIOMED NV (MYNZ) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for MYNZ stock?

The Earnings per Share (EPS) of MAINZ BIOMED NV (MYNZ) is expected to grow by 83.39% in the next year.